Présentation de l'entreprise
Firefly Neuroscience, Inc. operates as a medical technology and artificial intelligence enterprise dedicated to developing neuroscientific solutions that enhance brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company specializes in Brain Network Analytics, a software platform specifically designed to focus on diagnostic capabilities within the healthcare sector. This entity functions within the broader Technology sector, specifically categorized under the Software - Application industry, positioning it as a provider of specialized computational tools rather than consumer-facing applications. The company currently maintains a market capitalization of $26.71M and generates annual revenue of $1.14M over the trailing twelve months, while its employee count is listed as unavailable. These financial metrics indicate that Firefly Neuroscience is a micro-cap entity with a relatively small revenue base, suggesting it is in an early-stage growth phase where capital allocation prioritizes research and development over profitability or dividend distribution.
Santé financière
Over the trailing twelve months, Firefly Neuroscience reported a revenue of $1.14M, accompanied by a net income of $-24,531,000 and an EBITDA of $-8,464,000. The significant disparity between the revenue figure of $1.14M and the net loss of approximately $24.5M reveals an extremely high cost structure characterized by substantial operating expenses that far exceed current sales, a typical trait for deep-tech companies in the pre-profitability stage. The company generated a free cash flow of $-6,578,250, indicating that its cash burn rate is currently negative, which implies limited financial flexibility without additional capital injections or funding rounds. The gross margin stands at 56.5%, suggesting a favorable cost of goods sold structure relative to sales, whereas the operating margin is reported at -583.0% and the profit margin at 0.0%, highlighting that operating expenses are disproportionately large compared to the revenue base. In terms of solvency, the company holds $2.75M in cash against $0 in debt, resulting in a debt-to-equity ratio that is effectively N/A due to the absence of debt obligations, which portrays a conservative balance sheet free from leverage risk. The current ratio is 1.43, indicating that the company possesses sufficient current assets to cover its short-term liabilities, thereby maintaining adequate liquidity for its immediate operational needs. Furthermore, the return on equity is -547.6% and the return on assets is -70.9%, metrics that mathematically reflect the company's current inability to generate profit from its shareholder capital or asset base, underscoring that management is currently focused on scaling the business rather than delivering returns to investors.
Évaluation de la valorisation
The trailing P/E ratio and forward P/E ratio are both listed as N/A, which implies that earnings-based valuation models are not applicable given the company's significant net losses and the absence of projected earnings for the immediate future. The price-to-book ratio is 3.11, indicating that the market values the company's equity at more than three times its book value, which suggests a market premium attributed to the potential future value of its intellectual property and technological assets. The price-to-sales ratio is 23.39, and the EV/EBITDA is -2.65; these alternative valuation metrics suggest that investors are pricing the stock based on revenue potential and asset backing rather than current profitability or cash generation capabilities. The 52-week high is $4.51 and the 52-week low is $0.62, providing a trading range that reflects significant volatility and investor sentiment shifts over the past year. While the exact current price is not explicitly defined as a static number in the provided facts, the valuation metrics relative to the 52-week range indicate that the stock price has experienced substantial movement, with the market currently valuing the equity significantly above the lowest point of the year but potentially below the peak if one were to consider the implied spread from the high. The beta value is listed as N/A, meaning that standard market volatility comparisons relative to the broader market cannot be quantified with the available data, preventing a definitive assessment of price sensitivity to market swings.
Growth & Income
Firefly Neuroscience recorded a revenue growth of 677.4% year-over-year, while the earnings growth is N/A due to the company's continued net losses. Since earnings are negative, they cannot grow at a meaningful rate relative to revenue in the traditional sense, implying that the company is in a phase where top-line expansion is occurring despite the absence of bottom-line profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute cash to shareholders but instead retains all earnings to reinvest into its research and development activities. This reinvestment strategy is consistent with the company's growth profile, where the primary objective is to build market share and refine its artificial intelligence solutions rather than providing current income streams. The overall growth and income profile is characterized by explosive top-line expansion coupled with significant cash burn, zero dividend distribution, and a valuation structure that relies heavily on future growth expectations rather than current financial performance.